Says targeting double digit top-line growth and margin expansion into 2024. Says inflation pressures "normalizing a little bit." Expects steady improvement in inflation over next few years. Says has been able to take pricing in consumer business. Says "committed to strong and growing dividend." Says will pursue M&A if it’s a "strategic fit."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott Gains on Q1 Beat
- Abbott reports Q1 worldwide Medical Devices sales up 8.5% on reported basis
- Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business
- Abbott backs FY23 organic sales growth ‘at least’ high single digits
- Abbott reports Q1 adjusted EPS $1.03, consensus 99c